The helminth HIV connection: Time to act

AIDS

Volumn 22, Issue 13, 2008, Pages 1611-1614

  Bentwich, Zvi ^a   Teicher, Carrie Lee ^b   Borkow, Gadi ^c  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c Cupron Inc   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN E; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 5;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AFRICA; ASCARIS LUMBRICOIDES; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; DISEASE COURSE; EDITORIAL; EOSINOPHIL; HELMINTHIASIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMIGRANT; IMMUNE RESPONSE; ISRAEL; MIXED INFECTION; NECATOR AMERICANUS; PRIORITY JOURNAL; SCHISTOSOMA MANSONI; VACCINATION; VERTICAL TRANSMISSION; VIRUS LOAD; ANIMAL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; NOTE; PARASITOLOGY; TH2 CELL; TREATMENT OUTCOME;

ANIMALS; CD4 LYMPHOCYTE COUNT; HELMINTHIASIS; HIV INFECTIONS; HIV-1; HUMANS; LYMPHOCYTE ACTIVATION; TH2 CELLS; TREATMENT OUTCOME;

EID: 52249097017     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32830a506e     Document Type: Editorial

References (51)

1. Bentwich Z, Kalinkovich A, Weisman Z. Immune activation is a dominant factor in the pathogenesis of African AIDS. Immunol Today 1995; 16:187-191.
2. Bentwich Z, Weisman Z, Grossman Z, Galai N, Kalinkovich A. Pathogenesis of AIDS in Africa: lessons from the Ethiopian immigrants in Israel. Immunologist 1997; 5:21-26.
3. Bentwich Z, Weisman Z, Moroz C, Bar-Yehuda S, Kalinkovich A. Immune dysregulation in Ethiopian immigrants in Israel: relevance to helminth infections? Clin Exp Immunol 1996; 103:239-243.
4. Kalinkovich A, Weisman Z, Greenberg Z, Nahmias J, Eitan S, Stein M, et al. Decreased CD4 and increased CD8 counts with T cell activation is associated with chronic helminth infection. Clin Exp Immunol 1998; 114:414-421.
5. Borkow G, Weisman Z, Leng Q, Stein M, Kalinkovich A, Wolday D, et al. Helminths, human immunodeficiency virus and tuberculosis. Scand J Infect Dis 2001; 33:568-571.
6. Borkow G, Bentwich Z. Chronic immune activation associated with chronic helminthic and human immunodeficiency virus infections: role of hyporesponsiveness and anergy. Clin Micro-biol Rev 2004; 17:1012-1030; Table.
7. Bentwich Z, Kalinkovich A, Weisman Z, Grossman Z. Immune activation in the context of HIV infection. Clin Exp Immunol 1998; 111:1-2.
8. Bentwich Z, Kalinkovich A, Weisman Z, Borkow G, Beyers N, Beyers AD. Can eradication of helminthic infections change the face of AIDS and tuberculosis? Immunol Today 1999; 20:485-487.
9. Borkow G, Bentwich Z. Eradication of helminthic infections may be essential for successful vaccination against HIV and tuberculosis. Bull World Health Organ 2000; 78:1368-1369.
10. Borkow G, Bentwich Z. Host background immunity and human immunodeficiency virus protective vaccines, a major consideration for vaccine efficacy in Africa and in developing countries. Clin Diagn Lab Immunol 2002; 9:505-507.
11. Chan MS. The global burden of intestinal nematode infections: fifty years on. Parasitol Today 1997; 13:438-443.
12. Actor JK, Shirai M, Kullberg MC, Buller RM, Sher A, Berzofsky JA. Helminth infection results in decreased virus-specific CD8R cytotoxic T-cell and Th1 cytokine responses as well as delayed virus clearance. Proc Natl Acad Sci USA 1993; 90:948-952.
13. Cooper PJ, Espinel I, Paredes W, Guderian RH, Nutman TB. Impaired tetanus-specific cellular and humoral responses following tetanus vaccination in human onchocerciasis: a possible role for interleukin-10. J Infect Dis 1998; 178:1133-1138.
14. Da'Dara AA, Lautsch N, DudekT, Novitsky V, LeeTH, Essex M, et al. Helminth infection suppresses T-cell immune response to HIV-DNA-based vaccine in mice. Vaccine 2006; 24:5211-5219.
15. Elias D, Wolday D, Akuffo H, Petros B, Bronner U, Britton S. Effect of deworming on human T cell responses to mycobac-terial antigens in helminth-exposed individuals before and after bacille Calmette-Guerin (BCG) vaccination. Clin Exp Immunol 2001; 123:219-225.
16. Gopinath R, Ostrowski M, Justement SJ, Fauci AS, Nutman TB. Filarial infections increase susceptibility to human immunodeficiency virus infection in peripheral blood mononuclear cells in vitro. J Infect Dis 2000; 182:1804-1808.
17. Kalinkovich A, Borkow G, Weisman Z, Tsimanis A, Stein M, Bentwich Z. Increased CCR5 and CXCR4 expression in Ethiopians living in Israel: environmental and constitutive factors. Clin Immunol 2001; 100:107-117.
18. Kallestrup P, Zinyama R, Gomo E, Butterworth AE, van Dam GJ, Erikstrup C, et al. Schistosomiasis and HIV-1 infection in rural Zimbabwe: implications of coinfection for excretion of eggs. J Infect Dis 2005; 191:1311-1320.
19. Kassu A, Tsegaye A, Wolday D, Petros B, Aklilu M, Sanders EJ, et al. Role of incidental and/or cured intestinal parasitic infections on profile of CD4R and CD8R T cell subsets and activation status in HIV-1 infected and uninfected adult Ethiopians. Clin Exp Immunol 2003; 132:113-119.
20. Kjetland EF, Ndhlovu PD, Gomo E, Mduluza T, Midzi N, Gwanzura L, et al. Association between genital schistosomiasis and HIV in rural Zimbabwean women. AIDS 2006; 20:593-600.
21. Lawn SD, Butera ST, Folks TM. Contribution of immune activation to the pathogenesis and transmission of human immunodeficiency virus type 1 infection. Clin Microbiol Rev 2001; 14:753-777.
22. McElroy MD, Elrefaei M, Jones N, Ssali F, Mugyenyi P, Barugahare B, et al. Coinfection with Schistosoma mansoni is associated with decreased HIV-specific cytolysis and increased IL-10 production. J Immunol 2005; 174:5119-5123.
23. Secor WE, Shah A, Mwinzi PM, Ndenga BA, Watta CO, Karanja DM. Increased density of human immunodeficiency virus type 1 coreceptors CCR5 and CXCR4 on the surfaces of CD4(R) T cells and monocytes of patients with Schistosoma mansoni infection. Infect Immun 2003; 71:6668-6671.
24. Shapira-Nahor O, Kalinkovich A, Weisman Z, Greenberg Z, Nahmias J, Shapiro M, et al. Increased susceptibility to HIV-1 infection of peripheral blood mononuclear cells from chronically immune-activated individuals. AIDS 1998; 12:1731-1733.
25. Wolday D, Mayaan S, Mariam ZG, Berhe N, SeboxaT, Britton S, et al. Treatment of intestinal worms is associated with decreased HIV plasma viral load. J Acquir Immune Defic Syndr 2002; 31:56-62.
26. Brown M, Kizza M, Watera C, Quigley MA, Rowland S, Hughes P, et al. Helminth infection is not associated with faster progression of HIV disease in coinfected adults in Uganda. J Infect Dis 2004; 190:1869-1879.
27. Elliott AM, Mawa PA, Joseph S, Namujju PB, Kizza M, Nakiyingi JS, et al. Associations between helminth infection and CD4R T cell count, viral load and cytokine responses in HIV-1 -infected Ugandan adults. Trans R Soc Trop Med Hyg 2003; 97:103-108.
28. Hosseinipour MC, Napravnik S, Joaki G, Gama S, Mbeye N, Banda B, et al. HIV and parasitic infection and the effect of treatment among adult outpatients in Malawi. J Infect Dis 2007; 195:1278-1282.
29. Lawn SD, Karanja DM, Mwinzia P, AndoveJ, Colley DG, Folks TM, et al. The effect of treatment of schistosomiasis on blood plasma HIV-1 RNA concentration in coinfected individuals. AIDS 2000; 14:2437-2443.
30. Modjarrad K, Zulu I, Redden DT, Njobvu L, Lane HC, Bentwich Z, et al. Treatment of intestinal helminths does not reduce plasma concentrations of HIV-1 RNA in coinfected Zambian adults. J Infect Dis 2005; 192:1277-1283.
31. Borkow G, Teicher C, Bentwich Z. Helminth-HIV coinfection: should we deworm? PLoS Negl Trop Dis 2007; 1:e160.
32. Brown M, Mawa PA, Kaleebu P, Elliott AM. Helminths and HIV infection: epidemiological observations on immunological hypotheses. Parasite Immunol 2006; 28:613-623.
33. Walson JL, John-Stewart G. Treatment of helminth co-infection in individuals with HIV-1: a systematic review of the literature. PLoS Negl Trop Dis 2007; 1:e102.
34. Ayash-Rashkovsky M, Chenine AL, Steele LN, Lee SJ, Song R, Ong H, et al. Coinfection with Schistosoma mansoni reactivates viremia in rhesus macaques with chronic simian-human immunodeficiency virus clade C infection. Infect Immun 2007; 75:1751-1756.
35. Chenine AL, Buckley KA, Li PL, Rasmussen RA, Ong H, Jiang S, et al. Schistosoma mansoni infection promotes SHIV clade C replication in rhesus macaques. AIDS 2005; 19:1793-1797.
36. Chenine AL, Shai-Kobiler E, Steele LN, Ong G, Augostini P, Song R, et al. Acute Schistosoma mansoni infection increases susceptibility to systemic SHIV clade C infection in rhesus macaques after mucosal virus exposure. Plos NTD (in press).
37. Brenchley JM, Schacker TW, Ruff LE, Price DA, Taylor JH, Beilman GJ, et al. CD4R T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 2004; 200:749-759.
38. Douek D. HIV disease progression: immune activation, microbes, and a leaky gut. Top HIV Med 2007; 15:114-117.
39. Walson JL, Otieno PA, Mbuchi M, Richardson BA, Lohman-Payne B. Albendazole treatment among adults with HIV-1 and helminth co-infection: a randomized double blind placebo trial. AIDS 2008; 22:1601-1609.
40. Kallestrup P, Zinyama R, Gomo E, Butterworth AE, Mudenge B, van Dam GJ, et al. Schistosomiasis and HIV-1 infection in rural Zimbabwe: effect of treatment of schistosomiasis on CD4 cell count and plasma HIV-1 RNA load. J Infect Dis 2005; 192: 1956-1961.
41. Fauci AS. Multifactorial nature of human immunodeficiency virus disease: implications for therapy. Science 1993; 262: 1011-1018.
42. Bentwich Z, Maartens G, Torten D, Lal AA, Lal RB. Concurrent infections and HIV pathogenesis. AIDS 2000; 14:2071-2081.
43. Stein DS. Herpes virus infections, HIV, and disease progression. AIDS Clin Care 1995; 7:11-14; 18.
44. Webster A. Cytomegalovirus as a possible cofactor in HIV disease progression. J Acquir Immune Defic Syndr 1991; 4 (Suppl 1):S47-S52.
45. Junpo HA. Report on the global HIV/AIDS epidemic. Geneva, Switzerland: UNAIDS; 2007.
46. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342:921-929.
47. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272:1167-1170.
48. Fideli US, Allen SA, Musonda R, Trask S, Hahn BH, Weiss H, et al. Virologic and immunologic determinants of heterosexual transmission of human immunodeficiency virus type 1 in Africa. AIDS Res Hum Retroviruses 2001; 17:901-910.
49. Leroy V, Montcho C, Manigart O, Van de PP, Dabis F, Msellati P, et al. Maternal plasma viral load, zidovudine and mother-to-child transmission of HIV-1 in Africa: DITRAME ANRS 049a trial. AIDS 2001; 15:517-522.
50. Rousseau CM, Nduati RW, Richardson BA, Steele MS, John-Stewart GC, Mbori-Ngacha DA, et al. Longitudinal analysis of human immunodeficiency virus type 1 RNA in breast milk and of its relationship to infant infection and maternal disease. J Infect Dis 2003; 187:741-747.
51. UNAIDS. Joint United Nations Program on HIV/AIDS. Table of country-specific HIV/AIDS estimates and data report on the global HIV/AIDS epidemic; 2002. http://www.unaids.org/ epidemic-update/report/index.html.